Programme Documents & Resources: Diabetes
Levemir® discontinuation guidance
In September 2024, Novo Nordisk Ireland informed the Health Products Regulatory Authority (HPRA) and healthcare professionals working in diabetes in Ireland of their intention to discontinue Levemir® (insulin detemir) in both Penfill® and Flexpen® forms. Irish supply will end by December 2026. These presentations will be discontinued across all EU/EEA countries where they are marketed. No other Levemir® presentation will be available.
Clinical guidance for healthcare professionals
The HSE has developed clinical guidance to support health care professionals in selecting and safely initiating alternative basal insulins in advance of the Levemir® (insulin detemir) discontinuation.
Information for patients
A patient information leaflet has been produced by the HSE to inform and support patients through this change. Healthcare professionals are asked to distribute this information leaflet to any patients in your care that are currently prescribed or supplied with Levemir®.
HSE patient information leaflet for discontinuation of Levemir® insulin
Diabetes Prevention Programme
HSE Self-Management Education Programme for people with pre-diabetes
This report describes the process of design, development, pilot and evaluation of the Diabetes Prevention Programme.
HSE Diabetes Prevention Programme Evaluation Report 2023 (PDF, size 6.1 MB, 54 pages)
DISCOVER DIABETES - Type 2
A Diabetes Self-Management Education and Support (DSMES) Programme for the HSE to support people living with type 2 diabetes
This report describes the process of the design, development, piloting and evaluation of the programme, resulting in a clinically effective group type 2 DSMES programme for the HSE.
HSE DISCOVER DIABETES - Type 2 SMES Programme Evaluation Report 2024 (PDF, size 5 MB, 135 pages)